CD8A and neoplasm: However, in post-hoc subgroup analysis, hypermutator tumor (mismatch repair deficiency and somatic POLE/POLD1 mutations) and tumors resembling PXA (driven by BRAFV600E or NF1 mutation) display an increased content of CD8+ infiltrating T lymphocytes and longer survival upon addition of Bevacizumab, while Histone 3-mutated subgroups do not have CD8+ T lymphocyte infiltration and display a worse outcome [80].